AAAAAA

   
Results: 1-11 |
Results: 11
CLINICAL AND ECONOMIC COMPARISON OF SERTRALINE AND FLUOXETINE IN THE TREATMENT OF DEPRESSION - A 6-MONTH DOUBLE-BLIND-STUDY IN A PRIMARY-CARE SETTING IN FRANCE
Authors: BOYER P DANION JM BISSERBE JC HOTTON JM TROY S
Citation: P. Boyer et al., CLINICAL AND ECONOMIC COMPARISON OF SERTRALINE AND FLUOXETINE IN THE TREATMENT OF DEPRESSION - A 6-MONTH DOUBLE-BLIND-STUDY IN A PRIMARY-CARE SETTING IN FRANCE, PharmacoEconomics, 13(1), 1998, pp. 157-169
ABSOLUTE BIOAVAILABILITY AND ELECTROENCEPHALOGRAPHIC EFFECTS OF CONVENTIONAL AND EXTENDED-RELEASE FORMULATIONS OF VENLAFAXINE IN HEALTHY-SUBJECTS
Authors: PATAT A TROY S BURKE J TROCHERIE S DANJOU P LECOZ F ALLAIN H GANDON JA
Citation: A. Patat et al., ABSOLUTE BIOAVAILABILITY AND ELECTROENCEPHALOGRAPHIC EFFECTS OF CONVENTIONAL AND EXTENDED-RELEASE FORMULATIONS OF VENLAFAXINE IN HEALTHY-SUBJECTS, Journal of clinical pharmacology, 38(3), 1998, pp. 256-267
DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER, PHARMACODYNAMIC STUDY OF 10 AND 20 MG DOSES OF ZALEPLON AND ZOLPIDEM
Authors: DROVER DR LEMMENS HJM NAIDU S CEVALLOS WH TROY S MARTIN PT STANSKI DR
Citation: Dr. Drover et al., DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER, PHARMACODYNAMIC STUDY OF 10 AND 20 MG DOSES OF ZALEPLON AND ZOLPIDEM, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 105-105
ABSOLUTE AND COMPARATIVE SUBCUTANEOUS BIOAVAILABILITY OF ARDEPARIN SODIUM, A LOW-MOLECULAR-WEIGHT HEPARIN
Authors: TROY S FRUNCILLO R OZAWA T MAMMEN E HOLLOWAY S CHIANG S
Citation: S. Troy et al., ABSOLUTE AND COMPARATIVE SUBCUTANEOUS BIOAVAILABILITY OF ARDEPARIN SODIUM, A LOW-MOLECULAR-WEIGHT HEPARIN, Thrombosis and haemostasis, 78(2), 1997, pp. 871-875
POPULATION PHARMACOKINETICS OF INTRAVENOUS AMIODARONE AND COMPARISON WITH 2-STAGE PHARMACOKINETIC ANALYSIS
Authors: VADIEI K TROY S KORTHBRADLEY J CHIANG ST ZIMMERMAN JJ
Citation: K. Vadiei et al., POPULATION PHARMACOKINETICS OF INTRAVENOUS AMIODARONE AND COMPARISON WITH 2-STAGE PHARMACOKINETIC ANALYSIS, Journal of clinical pharmacology, 37(7), 1997, pp. 610-617
VENLAFAXINES LOW DRUG-INTERACTION POTENTIAL BASED ON CYTOCHROME-P450 - IN-VIVO EVIDENCE CONFIRMING IN-VITRO DATA OF LOW CYP2D6 AND NO CYP3A4 INHIBITION
Authors: AMCHIN J ALBANO D TROY S ERESHEFSKY L
Citation: J. Amchin et al., VENLAFAXINES LOW DRUG-INTERACTION POTENTIAL BASED ON CYTOCHROME-P450 - IN-VIVO EVIDENCE CONFIRMING IN-VITRO DATA OF LOW CYP2D6 AND NO CYP3A4 INHIBITION, Psychosomatics, 38(2), 1997, pp. 212-212
ABSOLUTE BIOAVAILABILITY AND EEG EFFECTS OF CT AND ER VENLAFAXINE FORMULATION
Authors: PATAT A TROCHERIE S LECOZ F TROY S BURKE J DANJOU P ALLAIN H GANDON JM
Citation: A. Patat et al., ABSOLUTE BIOAVAILABILITY AND EEG EFFECTS OF CT AND ER VENLAFAXINE FORMULATION, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 62-62
PHARMACOKINETICS OF THE ALDOSE REDUCTASE INHIBITOR TOLRESTAT - STUDIES IN HEALTHY-YOUNG AND ELDERLY MALE AND FEMALE SUBJECTS AND IN SUBJECTS WITH DIABETES
Authors: FRUNCILLO R TROY S PARKER V MAYERSOHN M HICKS D KRAML M BATTLE M CHIANG S
Citation: R. Fruncillo et al., PHARMACOKINETICS OF THE ALDOSE REDUCTASE INHIBITOR TOLRESTAT - STUDIES IN HEALTHY-YOUNG AND ELDERLY MALE AND FEMALE SUBJECTS AND IN SUBJECTS WITH DIABETES, Clinical pharmacology and therapeutics, 59(6), 1996, pp. 603-612
THE DOSE PROPORTIONALITY OF THE PHARMACOKINETICS OF ARDEPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN, IN HEALTHY-VOLUNTEERS
Authors: TROY S FRUNCILLO R OZAWA T MAMMEN E HOLLOWAY S CHIANG S
Citation: S. Troy et al., THE DOSE PROPORTIONALITY OF THE PHARMACOKINETICS OF ARDEPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN, IN HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 35(12), 1995, pp. 1194-1199
HOME-RANGE OF THE SWAMP WALLABY, WALLABIA BICOLOR
Authors: TROY S COULSON G
Citation: S. Troy et G. Coulson, HOME-RANGE OF THE SWAMP WALLABY, WALLABIA BICOLOR, Wildlife research, 20(5), 1993, pp. 571-577
INTRAVENOUS LOW-MOLECULAR-WEIGHT HEPARIN VS HEPARIN FOR THE INITIAL TREATMENT OF DEEP-VEIN THROMBOSIS
Authors: MERLI G COMP P ELLIOTT G ROSSI M TROY S HOLLOWAY S
Citation: G. Merli et al., INTRAVENOUS LOW-MOLECULAR-WEIGHT HEPARIN VS HEPARIN FOR THE INITIAL TREATMENT OF DEEP-VEIN THROMBOSIS, Thrombosis and haemostasis, 69(6), 1993, pp. 1117-1117
Risultati: 1-11 |